CONTINUE TO SITE
OR WAIT null SECS
Advertisement
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
The COVID-19 Pandemic and Its Positive Impact on RNA Drug Development
Published on:
Marina Necdina
Pharmaceutical Technology, The Real Message Behind Commercial mRNA Products, April 2023 eBook, Volume 2023 eBook, Issue 3
Pages: 18–21
The COVID-19 pandemic helped to showcase RNA molecules and their therapeutic potential. There were also lessons learned in terms of drug delivery, manufacturing, logistics, and storage.
RNA-based therapeutics have been in development for decades. The RNA drug development trend was on the rise in early 2000s; however, its popularity went down due to unique challenges. The COVID-19 pandemic helped to bring a spotlight on RNA molecules and their therapeutic potential.There were also lessons learned in terms of drug delivery, manufacturing, logistics and storage. This is the silver lining of the pandemic, where necessity and emergency need for vaccine and therapy highlighted potential solutions. Hopefully, it also opens the door for novel RNA therapeutics.
Read this article in Pharmaceutical Technology’s The Real Message Behind Commercial mRNA Products eBook.
Advertisement
About the author
Marina Necdina is a business development manager, former pharma analyst, and research scientist.
Article details
Pharmaceutical Technology
eBook: The Real Message Behind Commercial mRNA Products
April 2023
Pages: 18–21
Citation
When referring to this article, please cite it as Necdina, M. The COVID-19 Pandemic and Its Positive Impact on RNA Drug Development. Pharmaceutical Technology's The Real Message Behind Commercial mRNA Products eBook (April 2023).
Editor's note: This article was original published online on Feb. 1, 2023 and updated on April 11, 2023 to include missing text.
